Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Equity Consolidated Statement of Equity

v3.23.1
Consolidated Statement of Equity Consolidated Statement of Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Directors
Common Stock
Employees
Common Stock
Executive Officers
Common Stock
Balance, beginning of period, shares at Mar. 31, 2020   32,916,818            
Balance, beginning of period at Mar. 31, 2020 $ 346,439 $ 33 $ 227,741 $ 182,559 $ (63,894)      
Issuance of common stock in exercise of stock options, shares   97,156            
Issuance of common stock in exercise of stock options 629   629          
Issuance of restricted stock as deferred compensation to employees and directors, shares           52,098    
Issuance of common stock in lieu of compensation, shares             88,254 71,482
Issuance of common stock as deferred compensation to employees 0              
Stock compensation expense 3,728   3,728          
Repurchase of employee stock units on vesting (784)   (784)          
Net income/(loss) 877     877        
Foreign curency translation adjustment 28,615       28,615      
Other (632)       (640)      
Balance, end of period, shares at Mar. 31, 2021   33,225,808            
Balance, end of period at Mar. 31, 2021 378,872 $ 33 231,322 183,436 (35,919)      
Issuance of common stock in exercise of stock options, shares   8,100            
Issuance of common stock in exercise of stock options 97   97          
Issuance of restricted stock as deferred compensation to employees and directors, shares           32,136    
Issuance of common stock in lieu of compensation, shares             36,126 62,552
Issuance of common stock as deferred compensation to employees 0              
Stock compensation expense 3,803   3,803          
Repurchase of employee stock units on vesting (673)   (673)          
Net income/(loss) 20,092     20,092        
Foreign curency translation adjustment (2,922)       (2,922)      
Other $ (65)   (8)   (65)      
Balance, end of period, shares at Mar. 31, 2022 33,364,722 33,364,722            
Balance, end of period at Mar. 31, 2022 $ 399,204 $ 33 234,549 203,528 (38,906)      
Issuance of restricted stock as deferred compensation to employees and directors, shares           38,137    
Issuance of common stock in lieu of compensation, shares             40,923 64,294
Issuance of common stock as deferred compensation to employees 0              
Stock compensation expense 5,954   5,954          
Repurchase of employee stock units on vesting (643)   (643)          
Net income/(loss) 33,666     33,666        
Foreign curency translation adjustment (19,202)       (19,202)      
Other $ 9     (1) 8      
Balance, end of period, shares at Mar. 31, 2023 33,508,076 33,508,076            
Balance, end of period at Mar. 31, 2023 $ 418,988 $ 33 $ 239,860 $ 237,195 $ (58,100)